伐地那非结构式
|
常用名 | 伐地那非 | 英文名 | Vardenafil |
---|---|---|---|---|
CAS号 | 224785-90-4 | 分子量 | 488.60 | |
密度 | 1.4±0.1 g/cm3 | 沸点 | 692.2ºC at 760mmHg | |
分子式 | C23H32N6O4S | 熔点 | 214-216ºC | |
MSDS | N/A | 闪点 | 372.5ºC | |
符号 |
GHS02, GHS07 |
信号词 | Danger |
伐地那非用途Vardenafil是PDE5抑制剂,可作用于勃起功能障碍。 |
||||
伐地那非作用起效时间快,15至30分钟之内见效。副作用小,但因个体的差异,仍有不足2%的人会略感轻微头痛。溶于水和乙醇的特性,是目前做壮阳酒类、软胶囊及口服液的理想原料,持续时间可达6小时以上。 |
中文名 | 盐酸瓦地那非三水合物 |
---|---|
英文名 | vardenafil |
中文别名 | 伐地那非 | 2-[2-乙氧基-5-(4-乙基-哌嗪-1-磺酰基)苯基]-5-甲基-7-丙基-3H-咪唑[5,1-f]-[1,2,4]三联氮-4-酮单盐酸盐三水合物 | 伐地那非三水合盐酸盐 | 盐酸伐地那非 |
英文别名 | 更多 |
描述 | Vardenafil是PDE5抑制剂,可作用于勃起功能障碍。 |
---|---|
相关类别 | |
参考文献 |
密度 | 1.4±0.1 g/cm3 |
---|---|
沸点 | 692.2ºC at 760mmHg |
熔点 | 214-216ºC |
分子式 | C23H32N6O4S |
分子量 | 488.60 |
闪点 | 372.5ºC |
PSA | 121.28000 |
LogP | 2.65 |
外观性状 | 白色结晶粉末 |
蒸汽压 | 5.17E-19mmHg at 25°C |
折射率 | 1.656 |
储存条件 | ?20°C |
符号 |
GHS02, GHS07 |
---|---|
信号词 | Danger |
危害声明 | H225-H302 + H312 + H332-H319 |
警示性声明 | P210-P261-P302 + P352 + P312-P304 + P340 + P312-P337 + P313-P403 + P235 |
危害码 (欧洲) | F,Xn |
风险声明 (欧洲) | 11-20/21/22-36 |
安全声明 (欧洲) | 16-36/37 |
危险品运输编码 | UN1230 - class 3 - PG 2 - Methanol, solution |
~% 伐地那非 224785-90-4 |
文献:US2007/197535 A1, ; Page/Page column 6 ; |
~% 伐地那非 224785-90-4 |
文献:WO2013/75680 A1, ; Page/Page column 17 ; |
~% 伐地那非 224785-90-4 |
文献:WO2013/75680 A1, ; |
伐地那非上游产品 3 | |
---|---|
伐地那非下游产品 0 |
Improvement of exercise capacity in monocrotaline-induced pulmonary hypertension by the phosphodiesterase-5 inhibitor Vardenafil.
Respir. Physiol. Neurobiol. 186(1) , 61-4, (2013) Vardenafil, a phosphodiesterase-5 inhibitor, is approved for the therapy of erectile dysfunction. However, in contrast to Sildenafil and Tadalafil, little is known about its effects on pulmonary hyper... |
|
SOP conservative (medical and mechanical) treatment of erectile dysfunction.
J. Sex. Med. 10(1) , 130-71, (2013) Erectile dysfunction (ED) is the most frequently treated male sexual dysfunction worldwide. ED is a chronic condition that exerts a negative impact on male self-esteem and nearly all life domains incl... |
|
High inter-individual variability of vardenafil pharmacokinetics in patients with pulmonary hypertension.
Eur. J. Clin. Pharmacol. 69(2) , 197-207, (2013) To evaluate the pharmacokinetic parameters of a single oral dose of vardenafil in patients with pulmonary hypertension (PH).Sixteen patients with PH received vardenafil in single oral doses (20, 10 or... |
Vardenafil (INN) |
Vivanza |
2-{2-Ethoxy-5-[(4-ethylpiperazin-1-yl)sulfonyl]phenyl}-5-methyl-7-propylimidazo[5,1-f][1,2,4]triazin-4(1H)-one |
4-[2-ethoxy-5-(4-ethyl-piperazine-1-sulfonyl)-phenyl]-9-methyl-7-propyl-3,5,6,8-tetrazabicyclo[4.3.0]nona-3,7,9-trien-2-one |
Vardenafil hydrochloride trihydrate |
[14C]-Vardenafil |
2-{2-Ethoxy-5-[(4-ethyl-1-piperazinyl)sulfonyl]phenyl}-5-methyl-7-propylimidazo[5,1-f][1,2,4]triazin-4(1H)-one |
2-[2-ethoxy-5-(4-ethylpiperazin-1-yl)sulfonylphenyl]-5-methyl-7-propyl-1H-imidazo[5,1-f][1,2,4]triazin-4-one |
Vardenafil HCl Trihydrate |
4-[2-eyhoxy-5-(4-ethylpiperazin-1-yl)sulfonyl-phenyl]-9-methyl-7-propyl-3,5,6,8-tetrazabicyclo[4,3,0] none 3,7,9 trien-2-one |
Imidazo[5,1-f][1,2,4]triazin-4(3H)-one, 2-[2-ethoxy-5-[(4-ethyl-1-piperazinyl)sulfonyl]phenyl]-5-methyl-7-propyl- |
vardenafil |
Levitra (TN) |